Dimerix agreed to buy Mission Therapeutics’ stalled, Phase 2-ready acute kidney injury candidate for $5 million upfront, with up to $287 million in milestones. The transaction, described as Mission’s program being transferred into Dimerix’s kidney disease development path, keeps the compound moving toward the next clinical phase. The deal highlights continued capital allocation to late-stage-ready candidates where clinical and regulatory risk can be de-risked with additional evidence-building steps.